TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05419518

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EXTERNAL BEAM RADIATION
Description: A minimum of three daily radiation therapy treatments are required in any given week. Any missed radiation treatments will be made up at the end of the treatment schedule, such that the total number of delivered 5 Gy fractions remains ten.
Study: NCT05706701

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine vaping visit 1 (free-base nicotine)
Description: Participants will receive the free-base form of four nicotine fluxes: 9, 18, 27, 35 μg/sec at one of their two visits. Participants will use the ENDS device with free-base nicotine and four fluxes in random order.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine vaping visit 1 (protonated nicotine)
Description: Participants will receive the protonated form of four nicotine fluxes: 9, 18, 27, 35 μg/sec at the other study visit. Participants will use the ENDS device with protonated nicotine and four fluxes in random order.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine vaping visit 2 (free-base nicotine)
Description: Participants who received protonated nicotine during visit 1 will now receive free-base nicotine fluxes for visit 2: 9, 18, 27, 35 μg/sec.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine vaping visit 2 (protonated nicotine)
Description: Participants who received free-base nicotine during visit 1 will now receive protonated nicotine fluxes for visit 2: 9, 18, 27, 35 μg/sec.
Study: NCT05936307

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High-definition transcranial direct current (HD-tDCS), active condition
Description: Participants will receive a session of active HD-tDCS at a current intensity of 2 mA for a duration of 25min. The placement of electrodes will be determined to specifically target the brain area that has been identified as being involved in the process of externalization, as evidenced by fMRI. During the stimulation, participants will be engaged in a computer-based externalization task.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: High-definition transcranial direct current (HD-tDCS), active condition
Description: Participants will receive a session of active HD-tDCS at a current intensity of 2 mA for a duration of 25min. The placement of electrodes will be determined to specifically target the brain area that has been identified as being involved in the process of externalization, as evidenced by fMRI. During the stimulation, participants will be engaged in a computer-based externalization task.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High-definition transcranial direct current (HD-tDCS), placebo condition
Description: Participants will receive a session of placebo HD-tDCS, which will be delivered following the same procedures as active HD-tDCS but the intensity of the current will be set at 2mA during the 30 first seconds at the beginning of the 25-min period of the stimulation, and equal to 0 mA for the reminding period of stimulation to simulate the tingling sensation often experienced by individuals during active stimulation.~The placement of electrodes will be determined to specifically target the brain area that has been identified as being involved in the process of externalization, as evidenced by fMRI. During the stimulation, participants will be engaged in a computer-based externalization task

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: High-definition transcranial direct current (HD-tDCS), placebo condition
Description: Participants will receive a session of placebo HD-tDCS, which will be delivered following the same procedures as active HD-tDCS but the intensity of the current will be set at 2mA during the 30 first seconds at the beginning of the 25-min period of the stimulation, and equal to 0 mA for the reminding period of stimulation to simulate the tingling sensation often experienced by individuals during active stimulation.~The placement of electrodes will be determined to specifically target the brain area that has been identified as being involved in the process of externalization, as evidenced by fMRI. During the stimulation, participants will be engaged in a computer-based externalization task
Study: NCT05813561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: DWP14012 40mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DWP14012
Description: DWP14012 40mg
Study: NCT06466200

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Schiff Test
Description: Use of an air syringe positioned perpendicular to the tooth surface at a distance of 1 cm. A scale to determine the intensity of DH was created, with the SASS (Shiff Analog Sensitivity Scale) ranging from 0 to 3 (0 being the absence of pain felt by the patient and 3 being pain considered intolerable). If the pain is greater than 1 then the patient is considered hypersensitive.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Schiff Test
Description: Use of an air syringe positioned perpendicular to the tooth surface at a distance of 1 cm. A scale to determine the intensity of DH was created, with the SASS (Shiff Analog Sensitivity Scale) ranging from 0 to 3 (0 being the absence of pain felt by the patient and 3 being pain considered intolerable). If the pain is greater than 1 then the patient is considered hypersensitive.

Intervention type: OTHER
Group type: OTHER
Intervention: GOHAI questionnaire
Description: Oral health-related quality of life assessment by questionnaire

Intervention type: OTHER
Group type: OTHER
Intervention: GOHAI questionnaire
Description: Oral health-related quality of life assessment by questionnaire

Intervention type: OTHER
Group type: OTHER
Intervention: OHIP questionnaire
Description: Oral health-related quality of life assessment by questionnaire

Intervention type: OTHER
Group type: OTHER
Intervention: OHIP questionnaire
Description: Oral health-related quality of life assessment by questionnaire

Intervention type: OTHER
Group type: OTHER
Intervention: DHEQ fr questionnaire
Description: dentin hypersensitivity and oral health-related quality of life assessment by questionnaire

Intervention type: OTHER
Group type: OTHER
Intervention: DHEQ fr questionnaire
Description: dentin hypersensitivity and oral health-related quality of life assessment by questionnaire
Study: NCT04630353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB-201 IV
Description: HB-201 given IV, one (1) time, on day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB-201 IV
Description: HB-201 given IV, one (1) time, 7 to 14 days prior to definitive chemoradiation.
Study: NCT05803707

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based Adapted Physical Activity
Description: There will be 8 weekly sessions at a time defined in advance for the same group and for the 8 sessions
Study: NCT05490082

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron, Propevirine, Solifenacin
Description: Efficacy comparison

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mirabegron, Propevirine, Solifenacin
Description: Efficacy comparison

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron, Propevirine, Solifenacin
Description: Efficacy comparison

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron, Propevirine, Solifenacin
Description: Efficacy comparison
Study: NCT06003764

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field
Description: low-frequency PEMFT (15 Hz, 50% intensity output for 5 s/min for 20 minutes)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: traditional skin care
Description: traditional skin care( the patients received the institutional standard skin care, which encompassed 3×/day application of topical, hydroactive colloid gel, from the first day of RT. In case of a painful skin reaction and/or moist desquamation, a foam, absorbent, self-adhesive silicone dressing was used. Additionally, the patient was advised to follow the general skin care guidelines (e.g., no tie, no electric shaving, no aftershave, gentle washing with or without mild soap, patting dry with a soft towel instead of rubbing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional skin care
Description: traditional skin care( the patients received the institutional standard skin care, which encompassed 3×/day application of topical, hydroactive colloid gel, from the first day of RT. In case of a painful skin reaction and/or moist desquamation, a foam, absorbent, self-adhesive silicone dressing was used. Additionally, the patient was advised to follow the general skin care guidelines (e.g., no tie, no electric shaving, no aftershave, gentle washing with or without mild soap, patting dry with a soft towel instead of rubbing
Study: NCT05043935

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: L-PRF with antimicrobial photodynamic therapy
Description: Application of L-PRF with antimicrobial photodynamic therapy in the defect

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: antimicrobial photodynamic therapy without L-PRF
Description: application of antimicrobial photodynamic therapy without L-PRF in the defect
Study: NCT04909762

Intervention type: OTHER
Group type: OTHER
Intervention: Early Rehabilitation and Mobilisation (ERM)
Description: Early rehabilitation/mobilisation (ERM) encompasses patient-tailored interventions, delivered individually or in a bundled package. It is provided by health professionals from multiple disciplines and care-givers within intensive care settings.
Study: NCT04993846

Intervention type: DIAGNOSTIC_TEST
Intervention: Dental plaque sampling
Description: Dental plaque sampling

Intervention type: DIAGNOSTIC_TEST
Intervention: Dental plaque sampling
Description: Dental plaque sampling

Intervention type: DIAGNOSTIC_TEST
Intervention: Dental plaque sampling
Description: Dental plaque sampling

Intervention type: DIAGNOSTIC_TEST
Intervention: Dental plaque sampling
Description: Dental plaque sampling

Intervention type: DIAGNOSTIC_TEST
Intervention: Dental plaque sampling
Description: Dental plaque sampling

Intervention type: DIAGNOSTIC_TEST
Intervention: qPCR
Description: qPCR

Intervention type: DIAGNOSTIC_TEST
Intervention: qPCR
Description: qPCR

Intervention type: DIAGNOSTIC_TEST
Intervention: qPCR
Description: qPCR

Intervention type: DIAGNOSTIC_TEST
Intervention: qPCR
Description: qPCR

Intervention type: DIAGNOSTIC_TEST
Intervention: qPCR
Description: qPCR
Study: NCT05617365

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Therapy and Exercise Therapy
Description: At the physician's discretion, each subject will receive a minimum of 4 treatments up to a maximum of 8 treatments over the 12-week duration of the study (Haas et. al., 2018). The patients may be treated in the seated, prone and/or supine positions. Duration of treatment will depend on the degree of documented dysfunction but will be limited to one half hour. The techniques utilized by the physician may vary for many reasons including the degree of restriction, acuity, or patient cooperation.~The THE protocol will involve subjects performing cyclic voluntary retraction and protrusion of their head.
Study: NCT05498727

Intervention type: DIAGNOSTIC_TEST
Intervention: Integration of SARS-CoV 2 Testing in HIV, MNCH and TB Clinics
Description: This study employs a quasi-experimental pre-and-post SARS-CoV-2 Ag-RDT integration design in all facilities implementing the 61 facilities in Cameroon and Kenya in Cameroon and Kenya.

Intervention type: DIAGNOSTIC_TEST
Intervention: Integration of SARS-CoV 2 Testing in HIV, MNCH and TB Clinics
Description: This study employs a quasi-experimental pre-and-post SARS-CoV-2 Ag-RDT integration design in all facilities implementing the 61 facilities in Cameroon and Kenya in Cameroon and Kenya.

Intervention type: DIAGNOSTIC_TEST
Intervention: Integration of SARS-CoV 2 Testing in HIV, MNCH and TB Clinics
Description: This study employs a quasi-experimental pre-and-post SARS-CoV-2 Ag-RDT integration design in all facilities implementing the 61 facilities in Cameroon and Kenya in Cameroon and Kenya.
Study: NCT04704050

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dronedarone 400 mg Oral Tablet
Description: Dronedarone is an anti-arrhythmic drug with properties belonging to Vaughan-Williams class I-IV.~Participants will receive dronedarone 400 mg tablet, to be taken orally and twice daily for 52 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a placebo tablet matching the physical appearance of dronedarone, to be taken orally and twice daily for 52 weeks.
Study: NCT00733798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131I-TM601
Description: After a single 20mCi/0.4 mg Imaging Dose of 131I-TM601, patients in the Dose Escalation Phase will be administered between 2-5 weekly doses of 131I-TM601 at 1.2 mCi/kg of lean body mass (specific activity of 131I-TM601 will be maintained at 50 mCi 131I/mg TM601 for all doses administered in this study.) Patients in the Efficacy Phase of the study will be treated at the Maximum Tolerated Dose established in the Dose Escalation Phase.
Study: NCT05115929

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Decompressive Laparotomy
Description: As described in the study protocol a long midline laparotomy is performed and open abdomen therapy using negative pressure dressings initiated to lower abdominal pressure and thereby improve venous return from the brain to lower intracranial pressure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Decompressive Craniectomy
Description: As described in the study protocol a sufficiently sized hemi-craniectomy is performed and the skin closed over the bony defect to allow cerebral swelling and thereby lower intracranial pressure.
Study: NCT05033041

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Study drug metoclopramide
Description: Intravenous administration of 4 mg metoclopramide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Study drug placebo administration
Description: Intravenous administration of placebo (sterile normal saline)
Study: NCT05244096

Intervention type: OTHER
Intervention: No intervention
Description: Observational study
Study: NCT05955066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 MG
Description: 1 capsule (4mg) daily for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule daily
Study: NCT06516120

Intervention type: BEHAVIORAL
Intervention: RGS-app
Description: Participants use the RGS-app on a smartwatch once for 1.5 hours during the measurement. The RGS-app consists of augmented reality games to provoke upper limb movement.

Intervention type: BEHAVIORAL
Intervention: RGS-app
Description: Participants use the RGS-app on a smartwatch once for 1.5 hours during the measurement. The RGS-app consists of augmented reality games to provoke upper limb movement.
Study: NCT04749199

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced mirror therapy
Description: Participants of the enhanced mirror therapy group will perform complex, randomized, finger opposition and reposition movements, using the thumb, index, middle, ring, and little fingers, and will be shown a 35% blurred visual feedback through the computerized mirror therapy device. Each participant will receive a mirror training session for 60 minutes each day, three times per week for four consecutive weeks.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Standard mirror therapy
Description: Participants allocated to this group will perform simple, sequential finger opposition and reposition movements, using the thumb, index, middle, ring, and little fingers, and will be shown a clear image of the exercising hand. Each participant will receive a mirror training session for 60 minutes each day, three times per week for four consecutive weeks.
Study: NCT04761250

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lifestyle
Description: Lifestyle intervention i.e. diet, exercise, smoking cessation, alcohol limitations, dietary supplementation
Study: NCT06478914

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Description: NMES unit manufactured by Enraf-Holland was be used to administer the neuromuscular electrical stimulation (NMES) The study involved adjusting the patient's hips, knees, and ankles to achieve a comfortable position. Two electrodes of NMES were used in the first study group and a placebo in the control group. The electrodes were placed on the popliteal fossa and fibular head, and each session was conducted for 15 minutes daily for 2 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-intensity laser therapy (LILT)
Description: The laser unit is a small, hand-held, class III laser product manufactured by Laserex Technology Pty Ltd Australia. It offers continuous and pulsed laser therapy, with continuous therapy being the most effective. The device has a maximum average power of 5 milliwatts, a wavelength of 820 nm, and a power density of 0.39 W/cm2.~Patients were treated as outpatients, receiving full explanations about the purpose, therapeutic, and physiological benefits of low-intensity laser therapy (LILT). They were relaxed in supine position, with hips and knees adjusted. The patient was irradiated in a continuous mode and direct contact method, 3 times per week for 2 months, at 1-cm intervals and across the surface in grids. The laser applicator was applied to the surface, maintaining contact for maximum penetration.
Study: NCT06403943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BaiDiZiYin Pill, ShenQiYiFei Pill
Description: Indications of BaidiZiyin Pill: Nourishing the lungs and kidneys, cooling blood and removing steam. Used as an adjunctive treatment for tuberculosis caused by lung and kidney deficiency and qi yin injury, including coughing, shortness of breath, dry cough with less phlegm, hot flashes and night sweats, cold and spontaneous sweating, hoarseness, palpitations, cold limbs, and emaciation.~Indications of ShenqiYifei Pill: expectorant and cough relieving. It is suitable for patients with pulmonary tuberculosis and spleen diseases, as well as phlegm dampness retention. Symptoms include short breath, low sound, clear and thin phlegm, limited appetite, bloating and loose stools, pale complexion, fatigue and chest tightness, emaciation, and fear of cold and spontaneous sweating.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti tuberculosis chemotherapy
Description: 2 months' intensive regimen of anti tuberculosis chemotherapy Recommended first-line anti tuberculosis regimen: 2HRZE

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti tuberculosis chemotherapy
Description: 2 months' intensive regimen of anti tuberculosis chemotherapy Recommended first-line anti tuberculosis regimen: 2HRZE
Study: NCT06433648

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ottobock CLeg4 + Ottobock foot
Description: Commercially available Ottobock CLeg 4 microprocessor knee unit and Ottobock foot.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ottobock CLeg4 + Ottobock foot
Description: Commercially available Ottobock CLeg 4 microprocessor knee unit and Ottobock foot.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SRALAB Hybrid Knee + Polycentric Ankle
Description: Experimental powered prosthesis: SRALAB Hybrid Knee and powered polycentric ankle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SRALAB Hybrid Knee + Polycentric Ankle
Description: Experimental powered prosthesis: SRALAB Hybrid Knee and powered polycentric ankle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SRALAB Hybrid Knee + Passive Ankle
Description: Experimental powered prosthesis: SRALAB Hybrid Knee and passive ankle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ottobock CLeg 4 + Polycentric Ankle
Description: Commercially available Ottobock CLeg 4 prosthetic knee and SRALAB powered polycentric ankle.
Study: NCT05232721

Intervention type: DIAGNOSTIC_TEST
Intervention: The new instrument and colonoscopy with pathological examination
Description: Detect hemoglobin in stool by the point-of-care testing instrument before colonoscopy, detect colon lesion using colonoscopy and pathological examination.
Study: NCT06525168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA414 Granules
Description: DA414 Granules single ascending doses. DA414 will be orally administrated at single ascending doses of 12.5 mg, 25mg, 50 mg, 100mg and 200 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DA414 placebo
Description: DA414 placebo single ascending doses. DA414 placebowill be orally administrated at single ascending doses of 25mg, 50 mg, 100mg and 200 mg.
Study: NCT05784675

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MOBI-CPR game
Description: Participants use MOBI-CPR game at home environment.
Study: NCT04479072

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 81 mg
Description: Subjects in the interventional arm will receive a daily dose of aspirin 81 mg, starting at their baseline visit and to be taken up to their 6-month follow-up visit.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in this group will receive a daily dose of a placebo pill, starting at their baseline visit and to be taken up to their 6-month follow-up visit.
Study: NCT05884580

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuflo BPH Treatment System
Description: The Neuflo BPH Treatment System is designed to treat patients with lower urinary tract symptoms (LUTS) associated with BPH. It is an outpatient-based, minimally invasive treatment option and uses hydrolysis to reduce prostatic tissue in the lateral lobes of the prostate. Reduced pressure and constriction of the urethra alleviates urinary and other symptoms of BPH.
Study: NCT05833815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg
Description: Oral Everolimus 10 mg daily in addition to standard of care i.e. GemOx or CapOx

Intervention type: DRUG
Group type: OTHER
Intervention: Standard of care
Description: GemOx or CapOx
Study: NCT06433284

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 25-gauge pars plana vitrectomy with inverted flap technique and SF6 tamponade
Description: Standard 3 port 25-gauge pars plana vitrectomy with inverted flap technique after brilliant blue dye staining and SF6 tamponade. Flower petal type of inverted flap will be performed - multiple small ILM flaps will be created around the macular hole and placed over the macular hole

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 25-gauge pars plana vitrectomy with complete internal limiting membrane peeling with amniotic membrane hydrogel filling and SF6 tamponade
Description: Standard 3 port 25-gauge pars plana vitrectomy with complete internal limiting membrane peeling around the macular hole after brilliant blue dye staining then filling the hole with amniotic membrane hydrogel and sulfur hexafluoride (SF6) tamponade